标题
Trastuzumab emtansine: mechanisms of action and drug resistance
作者
关键词
Docetaxel, Trastuzumab, Metastatic Breast Cancer, Capecitabine, Lapatinib
出版物
BREAST CANCER RESEARCH
Volume 16, Issue 2, Pages -
出版商
Springer Nature
发表日期
2014-03-05
DOI
10.1186/bcr3621
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Abstract 4629: Tumor cells selected for resistance to an antibody-drug conjugate retain sensitivity to ADCs with modified linkers and payloads.
- (2014) Xingzhi Tan et al. CANCER RESEARCH
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
- (2013) G. D. L. Phillips et al. CLINICAL CANCER RESEARCH
- Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial
- (2013) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer
- (2013) Sherene Loi et al. JNCI-Journal of the National Cancer Institute
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
- (2012) E. Komlodi-Pasztor et al. CLINICAL CANCER RESEARCH
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
- (2012) Mattia Barbareschi et al. VIRCHOWS ARCHIV
- Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
- (2011) J. Huober et al. BREAST
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Enhanced Lysosomal Activity Is Involved in Bax Inhibitor-1-induced Regulation of the Endoplasmic Reticulum (ER) Stress Response and Cell Death against ER Stress
- (2011) Geum-Hwa Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
- (2011) Naoki Niikura et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitosis is not a key target of microtubule agents in patient tumors
- (2011) Edina Komlodi-Pasztor et al. Nature Reviews Clinical Oncology
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients
- (2011) Maurizio Scaltriti et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
- (2010) Y. V. Kovtun et al. CANCER RESEARCH
- Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
- (2010) Teemu T. Junttila et al. CANCER RESEARCH
- 223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance
- (2010) G. Li et al. EJC SUPPLEMENTS
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
- (2009) E. Yao et al. CLINICAL CANCER RESEARCH
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel inHER2-Positive Metastatic Breast Cancer
- (2009) Andrew M. Wardley et al. JOURNAL OF CLINICAL ONCOLOGY
- HER-2/neu expression in primary and metastatic breast cancer
- (2008) Elyse E. Lower et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Death through a tragedy: mitotic catastrophe
- (2008) H Vakifahmetoglu et al. CELL DEATH AND DIFFERENTIATION
- Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate
- (2008) D. L. Costantini et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now